The legal action, Darcy v. The Chemours Company et al., filed in the U.S. District Court for the District of Delaware, centers on the period between February 20 and August 4, 2026. According to the complaint, the company failed to disclose that it had significantly overstated aftermarket demand for its products, leading to an unsustainable inventory buildup that forced a downward revision of its full-year adjusted EBITDA guidance.
Chemours Faces Securities Class Action Following 18% Stock Plunge
An 18.63% single-day collapse in Chemours Company stock has triggered a securities class action lawsuit, with plaintiffs alleging the chemical manufacturer misled shareholders regarding the actual demand for its Opteon product line throughout the first half of 2026.
Management acknowledged the inventory glut during an August 4 earnings call, admitting that approximately $65 million in aftermarket sales had been prematurely allocated. Following this disclosure, shares plummeted by $3.34 to close at $14.59 on August 5. The Law Offices of Howard G. Smith, representing the plaintiffs, maintains that these undisclosed operational issues rendered the company's financial projections unreliable. Investors seeking to serve as lead plaintiff in the litigation must file their motions by the December 7, 2026, deadline.
Comments (0)
No comments yet. Be the first!